Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, migraine, addiction, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Feb 2, 2016
Heptares Launches “ORBIT” Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors...
Nov 30, 2015
Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. focused on GPCR Targets across Multiple Therapeutics Areas

Feb 15-16, 2016
SMI Advances and Progress in Drug Design
London, UK
Presenting: Ben Tehan

Feb 21-25, 2016
Keystone Meeting - G Protein-Coupled Receptors: Structure, Signaling and Drug Discovery
Keystone, CO, USA
Presenting: Fiona Marshall

© 2012-2016 Heptares Therapeutics